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We report on three new patients with spondyloocular syndrome (SOS) in a
consanguineous Pakistani family. All three patients present progressive generalized
osteoporosis, short stature, recurrent fractures, hearing loss and visual impairments.
WES revealed a novel homozygous frameshift variant in exon 11 of XYLT2 (NG
012175.1, NP_071450.2) resulting in loss of evolutionary conserved amino acid
sequences (840 – 865/865) at C-terminus p.R840fs∗115. Sanger Sequencing
confirmed the presence of the novel homozygous mutation in all three patients while the
parents were heterozygous carriers of the mutation, in accordance with an autosomal
recessive inheritance pattern. Only nine variants worldwide have previously been
reported in XYLT2 in patients with SOS phenotype. These three patients with novel
homozygous variant extend the genotypic and phenotypic spectrum of SOS.
Keywords: spondyloocular syndrome (SOS), whole-exome-sequencing (WES), osteoporosis, xylosyltransferase II
(XYLT2), cataract
INTRODUCTION
Spondyloocular syndrome (OMIM 605822), a very rare form of autosomal recessive genetic skeletal
dysplasia, was first defined and reported by Schmidt et al. (2001), Taylan et al. (2017). In recent
years, spondyloocular syndrome (SOS) has been linked to variant in the xylosyltransferase II
encoded by XYLT2 (MIM 608125) (Munns et al., 2015; Taylan et al., 2016). XYLT2 is involved in
the biosynthesis of proteoglycans (PGs).
PGs, surface-associated and extracellular matrix proteins, play a vital role in sustaining the
homeostasis in various tissues including skin, bone and cartilage (Couchman and Pataki, 2012).
PGs are composed of core protein on which glycosaminoglycan (GAGS) chains, made up of
tetrasaccharide linkers, are assembled. Mainly two types of sulfated PGs, heparin sulfate PGs and
chondroitin sulfate/dermatan sulfate PGs are involved (Couchman and Pataki, 2012). Synthesis
of tetrasaccharide linker molecules is catalyzed by four consecutive enzymatic reactions, first
reaction requiring the transfer of xylose from uridine diphosphate-xylose (UDP-Xyl) to particular
serine residue of the core protein by xylosyltransferase I (MIM 608124) and II. Next step involves
the addition of two galactose residues by galactosyltransferase I and II, encoded by B4GALT7
(MIM 604327) and B3GALT6 (MIM 615291), respectively. Final reaction involves the transfer
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of glucuronic acid by glucuronosyltransferase I, encoded by
B3GAT3 (MIM 606374). Variants in genes encoding these five
enzymes have been reported in various genetic skeletal diseases,
which are collectively known as linkeropathies (Mizumoto et al.,
2015; Taylan et al., 2016).
To date, only nine variants in XYLT2 have been identified in
the patients with SOS phenotype worldwide (Taylan et al., 2017;
Umair et al., 2017). Here we present a consanguineous Pakistani
family with three children with moderate to severe manifestations
of SOS due to a novel homozygous frameshift variant in XYLT2.
CASE PRESENTATION AND METHOD
We identified a consanguineous Pakistani family in which three
family members, 12 and 9 years old brothers (IV:1, IV:3) and
their 10 years old cousin (IV:5), were affected with a rare
skeletal dysplasia (Figure 1A,B). A written informed consent was
obtained from the head of family (father) before the collection
of blood samples for genetic analyses from all available family
members and publication of the results.
All three patients were under treatment in Children’s Hospital
Lahore, Pakistan. Growth parameters including height and
weight of patients, were measured and compared with reference
values (Aziz et al., 2012) among Pakistani population (Aziz et al.,
2012). The clinical data, including radiographs, were assessed
retrospectively. Genetic studies were performed using peripheral
blood genomic DNA. We used 1µg of genomic DNA for targeted
enrichment from Patient 1 (IV:1) using the Nimblegen SeqCap
EZ Exome v3 kit and barcoded for sequencing on a single lane
of a multiplexed 2x151 bp sequencing run on the Illumina
HiSeq 2000 platform. This individual’s sample was sequenced
to a mean coverage of 37.8 reads per target base, with 97%
of the target exome covered by 10 or more reads. Reads were
mapped using BWA v0.7.17 (Genomes Project et al., 2012) and
variants were called using the GATK v2 Unified Genotyper
following the recommended guidelines by GATK ‘Best practices
for variant calling v3’ (Genomes Project et al., 2012). Variants
present at ≤ 1% frequency in 1000 Genomes, HapMap and
ExAC populations were identified from exome sequencing
data. SIFT (Sim et al., 2012) and Polyphen2 (Adzhubei et al.,
2010) were used to predict effect of each missense variant.
The variant of interest was looked up within in-house exome
data of 95 Pakistani individuals (16 normal individuals and 79
individuals with an unrelated disease phenotype) which were
processed as described above. We used the following primer
sequences for the segregation analysis of detected mutations in





There were three patients in the family, the index Patient 1 (IV:1)
is a 12 years old boy born to consanguineous healthy parents from
uncomplicated pregnancy at full term. He presented with delayed
milestones and multiple compression fractures at the age of 9
months. His first right femoral fracture occurred at 12 months
and generalized osteoporosis was noted. Presently, his height is
124 cm (Z-score -2.4) and weight 36 kg (Z-score -0.2). Physical
evaluation revealed a low posterior hairline, short and webbed
neck, low set ears, shield chest, long fingers and toes. Sclerae
were normal and no dental problems were observed. Radiographs
revealed generalized osteoporosis, mild to moderate thoracic
kyphosis, platyspondyly and increased intervertebral disk space.
Intravenous pamidronate treatment was started at the age of 36
months and resulted in reshaping of some vertebrae. At the age
of 12 years the patient is ambulant but has unsteady gait due to
muscle weakness.
In addition to skeletal problems, the patient was diagnosed
with moderate hearing loss at 8 years of age. Eye examination
revealed nystagmus and amblyopia, and spontaneous left retinal
detachment occurred. Cataracts were noted at 12 years. Learning
difficulties were also obvious since early childhood. Biochemical
analysis of patient’s blood revealed normal levels of calcium,
alkaline phosphatase, creatinine and 25-OH-vitamin D.
The 2nd patient (IV:3) is 9 years old, younger brother of
patient 1, and had a similar clinical course and manifestations as
his elder brother. He was diagnosed with generalized vertebral
flattening and multiple compression fractures at the age of 6
months. Currently, his height is 109 cm (Z-score -3.5) and weight
29 kg (Z-score -0.7). He also had pamidronate infusions at the
age of 15 months. Reshaping of some vertebrae were noted, but
new compression fractures have also occurred. He has sustained
recurrent long bone fractures but is ambulant. Mild to moderate
hearing loss and vision impairment appeared at the age of 6
years and he also had learning difficulties. Biochemical analysis
of patient’s blood revealed normal levels of calcium, alkaline
phosphatase, creatinine and 25-OH-vitamin D.
The 3rd patient of the family (IV:4) is a 10 years old boy
who has had similar clinical course and manifestations as his
two older cousins. Presently, his height is 111 cm (Z-score -
3.7) and weight 33 kg (Z-score -0.4). Delayed milestones and
multiple compression fractures were apparent at the age of 9
months. His first femoral fracture occurred at the age of 18
months and generalized osteopenia was observed; multiple other
fractures have occurred thereafter. Physical evaluation revealed
a low posterior hairline, short and webbed neck, low set ears,
shield chest, long fingers and toes. Sclerae and teeth were
normal. Radiographs revealed moderate thoracic kyphosis and
platyspondyly. He started intravenous pamidronate treatment at
the age of 3 years which improved the compression fractures but
did not completely prevent new fractures. Along with skeletal
problems he was also diagnosed with hearing loss and visual
impairment at the age of 5 years. He was operated on for
bilateral cataract. Learning difficulties were observed since early
childhood. Blood biochemistry for calcium, alkaline phosphatase,
creatinine and 25-OH-vitamin D was normal.
Genetic Findings
We identified a total of 33,446 variants from WES of Patient
#1. Eight variants remained after filtering for variants which
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FIGURE 1 | (A) Pedigree of affected family. Arrow indicates the affected member whose DNA sample was processed for WES and asterisks indicate the family
members whose blood samples were collected and Sanger sequenced. (B) Photograph showing all the three patients from the SOS family IV:1, IV:3, and IV:4.
localized to coding regions, are non-synonymous, rare (allele
frequency ≤ 1%), autosomal recessive and predicted to be
damaging (Figure 2, Supplementary Table S1). Based on the
functions of the genes in which these 8 candidate variants
localized and the previously reported gene association with SOS,
we focused on the 17:g.48437571CAG>C deletion variant in
XYLT2 (xylosyltransferase II). The deletion g.48437572delAG
(p.R840Tfs∗115) which is present at 17q21.33 alters the reading
frame, substituting the last 25 amino acids (p.840 – 865)
at carboxy terminal end of the xylosyltransferase II. Sanger
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FIGURE 2 | Flowchart of variant filtering. A total of 33,446 variants were found
from WES of Patient 1. Eight candidate variants remain after filtering
(Supplementary Table S1).
sequencing confirmed that all three patients were homozygous
for this variant and their parents were heterozygous (Figure 3).
Two healthy siblings were negative for the variant. This variant
was not present in exome-sequencing data of 95 Pakistani
individuals, and was also not found in the available population
databases, including the exome aggregation consortium database
(ExAC) and genome aggregation database (gnomAD). This novel
variant segregated perfectly with SOS manifestations and was
regarded as the cause of the patient’s phenotype.
DISCUSSION
We report the phenotypic characteristics and molecular diagnosis
of SOS in three children from a consanguineous Pakistani family.
All three patients present with generalized osteoporosis, multiple
compression fractures, hearing loss and visual impairment,
all consistent with the diagnosis of SOS. We report a novel
homozygous pathogenic frameshift variant in XYLT2 in the
family under study. Chromosomal location of the XYLT2
is 17q21.3-q22. XYLT2 contains 11 exons and 10 introns,
and encodes an 865 amino acids long protein. The XYLT2
is comprised of four domains; N-terminus domain, catalytic
domain, a core2/I-branching enzyme domain and a C-terminus
domain (Umair et al., 2017). Schmidt et al. (2001) published
the first clinical report on SOS in a consanguineous Iraqi family
with 6 affected individuals. Alanay et al. (2006) reported in 2006
another patient with SOS in a Turkish family. Munns et al.
(2015) identified a pathogenic biallelic frameshift insertion in
XYLT2 as the genetic cause of SOS in a non-consanguineous
Australian European family with two affected brothers; another
patient had a deleterious homozygous frameshift deletion.
Taylan et al. (2016) identified a nonsense pathogenic frameshift
variant (p.Arg730∗) in a Turkish patient and two different
pathogenic missense variants (p.Arg563Gly and p.Leu605Pro)
FIGURE 3 | Segregation analysis. (A) Sanger sequencing results of healthy sibling (IV:2), arrows indicating no change. (B) Sequencing results of patient 1 (IV:1),
arrow indicating homozygous deletion of 2 bases. (C,D) Sequencing results of father (III:8) and mother (III:9), arrows indicating heterozygous deletion.
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in consanguineous Canadian and Iraqi families. To date, two
homozygous frameshift deletions, one homozygous frameshift
insertion, one homozygous nonsense and five homozygous
missense variants in XYLT2 with typical SOS phenotypic
characteristics have been reported (Taylan and Makitie, 2016;
Taylan et al., 2017; Umair et al., 2017; Table 1). Here, we
report a novel homozygous nonsense frameshift variant in a
consanguineous Pakistani family with three affected individuals
with manifestations of SOS including moderate to severe early-
childhood onset osteoporosis, multiple compression fractures,
gradual hearing loss and visual impairment. Our patients had a
frameshift change in exon 11 of XYLT2. The p.Ala174Profs∗35
and p.Val232Glyfs∗54 frameshifts previously reported by Munns
et al. (2015) in exon2 and 3 lead to premature termination
and truncated mRNA (Table 1). None of our patients currently
present with severe cardiac problems or congenital heart
defects. The described frameshift p.R840Tfs∗115, is predicted
to adversely affect the catalytic subunit of xylosyltransferase
II. The described frameshift results in the removal of the last
25 evolutionarily conserved amino acids in the last exon of
XYLT2 (exon11). Defects in exon 11 inhibit the catalysis of sugar
transfer to serine residue of PG core proteins thus resulting
in improper PGs synthesis. Phenotypic features in our patients
are more serious as compared with those reported in subjects
with homozygous missense mutations by Taylan et al. (2016),
It is possible that the single amino acid replacement described
by Taylan et al. (2016) may allow residual protein function
while in our patients the removal of 25 amino acids may result
in complete loss of XYLT2 function. All these patients have
been treated with pamidronate infusions, which has helped in
reducing the fractures but some new compression fractures still
occurred. As expected, pamidronate infusion did not improve
vision or hearing.
To date, all patients including our patients with SOS
manifestation and defect in xylosyltransferase II have showed
autosomal recessive pattern of inheritance, and no clinical
manifestations have been reported in a heterozygous state. This
finding suggests that only biallelic deleterious variants in XYLT2
lead to such a loss in enzyme function that clinical symptoms
appear, while in a heterozygous state the XYLT2 function is
compensated by the normal allele.
CONCLUSION
We identified a novel deleterious nonsense frame shift variant in
theXYLT2 in three children in a consanguineous Pakistani family.
This novel variant results in marked skeletal and extra-skeletal
features including generalized osteoporosis, platyspondyly,
gradual hearing loss, and visual impairment. Differences in
phenotypic presentations, from mild to severe forms, between
our and previously reported patients are likely to be dependent on
the nature and location of the variant along with the expression
pattern of XYLT2 in different tissues. Pamidronate therapy was
beneficial but did not fully restore the bone health.
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